Microenvironment and related genes predict outcomes of patients with cervical cancer: evidence from TCGA and bioinformatic analysis

WENXI GAO1,2,#; QIANQIAN MA3,9; CHENYU TANG3,5; YUELI ZHAN4; YINONG DUAN2; HUIHUA NI5,*; YUNZHAO XU5,6,*

1 Laboratory Center of Economics and Management School, Nantong University, Nantong, 226019, China
2 School of Medicine, Nantong University, Nantong, 226001, China
3 Department of Group Health Section, Wuxi Matemaland Child Health Care Hospital Affiliated of Nanjing Medical School, Wuxi, 214002, China
4 Department of Anesthesiology, Anxi County Maternal and Child Health Hospital, Quanzhou, 362400, China
5 Department of Obstetrics and Gynecology, Nantong University Affiliated Hospital, Nantong, 226001, China
6 Department of Obstetrics and Gynecology, School of Medicine, Nantong University, Nantong, 226001, China

Key words: TCGA, Immune scores, Prognosis, Cervical cancer

Abstract: Cervical cancer (CESC) is one of the most common cancers and affects the female genital tract. Consistent HPV infection status has been determined to be a vital cause of tumorigenesis. HPV infection may induce changes to the immune system and limit the host’s immune response. Immunotherapy is therefore essential to improving the overall survival of both locally advanced and recurrent CESC patients. Using 304 relevant samples from TCGA, we assessed immune cell function in CESC patients to better understand the status of both tumor micro-environment cells and immune cells in CESC. Functional enrichment analysis, pathway enrichment analysis, and PPI network construction were performed to explore the differentially expressed genes (DEGs). The analysis identified 425 DEGs, which included 295 up-regulated genes and 130 down-regulated genes. We established that upregulation of CCL5 was correlated with significantly better survival, meaning that CCL5 expression could serve as a novel prognostic biomarker for CESC patients. We further focused on CCL5 as a hub gene in CESC, as it had significant correlations with increased numbers of several types of immune cells. Cell-type fractions of M1 macrophages were significantly higher in the high-immune-scores group, which was associated with better overall survival. Finally, we concluded that CCL5 is a promising prognostic biomarker for CESC, as well as a novel chemotherapeutic target.

Introduction

Cervical cancer, including cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), is one of the most common cancers. Cervical cancer affects the female genital tract, and its onset is closely related to infection by human papillomavirus (HPV) (He et al., 2016). Currently, the yearly incidence of CESC is dramatically increasing, with a trend towards younger patient age.

As has been well-established, HPV is a vital factor in causing CESC (Sichero et al., 2019). Thanks to the widespread use of HPV vaccinations and extensive cervical screenings, more than 90% of CESC patients are curable when diagnosed during Stages I–II. However, surgical options for CESC patients who have reached an advanced stage by the time of diagnosis may not be available. In advanced cases, radiotherapy and chemotherapy may be used as an optional treatment in addition to surgery. However, some CESC patients with poor sensitivity to conventional radio-chemotherapy had worse overall survival outcomes with this approach.

Immunotherapeutic interventions are essential for advanced-stage patients in order to improve their overall survival (De Felice et al., 2018; Dyer et al., 2019). Immunotherapy is emerging as an available option to treat a variety of malignancies, such as melanoma and renal cancers, and interest in the field has been significantly increasing over the past few decades (Ramanathan et al., 2018). It has been reported that, because it can promote evasion from host T-cell immune-surveillance, HPV
Infection stimulates the progression of carcinogenesis from low-grade pathological changes to CESC (Chauhan and Bharadwaj, 2018; Whiteside, 2008). HPV infection could induce modifications to the immune system and limit the host’s immune response. These changes could include compromised cellular immune response, infiltration of regulatory T cells, an imbalance between Th1 and Th2 cells, macrophage differentiation, and DC activation.

A tumor’s growth micro-environment, created by tumor cells and dominated by tumor-induced interactions, is also composed of various immune cells that fail to appropriately exert anti-tumor effects (Mangino et al., 2016). Recently, some clinical studies have shown that immunotherapy can play a significant role in treating both locally advanced and recurrent/metastatic CESC patients (Rotman et al., 2018).

In recent years, the Cancer Genome Atlas (TCGA) has been leveraged to evaluate immune infiltration and improve poor prognoses for advanced-stage CESC patients (De Felice et al., 2018; Wu et al., 2019). Similarly, performed a comprehensive genome-wide study of gene expression data sets downloaded from TCGA in order to identify promising targets for novel anti-tumor therapies for CESC patients.

In our study, we examined immune cell function in CESC patients using 304 relevant samples from TCGA to investigate tumor micro-environment as it relates to CESC carcinogenesis and invasive progression. This analysis identified 425 differentially expressed genes (DEGs) within the “immune” category, of which 295 were up-regulated and 130 were down-regulated. GEPIA-sourced data and TIMER were then employed to analyze hub genes and their relationships to infiltration levels. We established that, in CESC patients, CCL5 expression levels showed significant correlations with levels of several immune cells, which could therefore collectively serve as potential prognostic biomarkers to predict survival in CESC patients. Furthermore, CD8+ T cells, M1 macrophages, M0 macrophages, and M2 macrophages may be candidate targets for CESC therapies. Further investigation should be performed to validate the clinical value of these markers.

Materials and Methods

Stromal and immune scores in CESC
We examined immune cell function in CESC patients using 304 relevant samples from TCGA (https://portal.gdc.cancer.gov/). An R ESTIMATE algorithm (https://www.r-project.org/) (R version 3.5.1), which infers tumor cellularity by exploiting unique transcriptional profile characteristics (Yoshihara et al., 2013), was applied to these samples and used to calculate their CESC immune scores.

Identification of differently expressed genes (DEGs)
Transcriptional data analysis was performed with the limma package in R, using cut-off criteria of |LogFC| > 2 and p-value < 0.01 to identify DEGs in high- and low-score groups (Ritchie et al., 2015).

Functional enrichment analysis
Enrichment analysis was performed using the clusterProfiler package in R in order to characterize biological processes (BP), cellular components (CC), and molecular functions (MF) associated with the DEGs (2006; Ashburner et al., 2000; Yu et al., 2012). KEGG pathway enrichment analysis was further used to identify relevant signaling pathways. KEGG is an extensive functional and metabolic pathway-ascertaining resource; its exhaustive database compiles abundant information on genomes, biological pathways, diseases, chemical substances, and drugs (Ogata et al., 1999). For these analyses, a p-value < 0.05 was considered statistically significant.

Protein-protein interaction (PPI) network construction and module analysis
The Search Tool for the Retrieval of Interacting Genes database (STRING, https://string-db.org/) resource is designed specifically to review PPI information (Szklarczyk et al., 2015). The DEGs identified previously were submitted to this database to evaluate their potential interactions; those interactions with a combined score > 0.4 were deemed significant and extracted for PPI network construction in Cytoscape (Smoot et al., 2011). Molecular Complex Detection (MCODE) was subsequently used to screen significant PPI network modules, with cutoffs set at degree = 2 and node score = 0.1, k-core set at 2 and maximum depth set at 100 (Bandettini et al., 2012). These modules were then analyzed for functional and pathway enrichment.

Selection and validation of hub genes
Module genes were validated via GEPIA (Gene Expression Profiling Interactive Analysis) and TIMER. GEPIA, made up of 8587 normal and 9736 tumor samples from the GTEx (Genotype-Tissue Expression) and TCGA databases (Tang et al., 2017), is an interactive web application tool that was used to confirm expression level reliability of CESC module genes relative to normal samples. We also explored the prognostic significance of these genes on this platform; those exhibiting significant differences were designated as hub genes, as they were closely correlated with patient prognosis.

Correlation between hub genes and immune cells
TIMER, as a comprehensive resource that systematically analyzes immune infiltrates across different cancers (https://cistrome.shinyapps.io/timer/) (Li et al., 2017), applies a statistical deconvolution methodology (Li et al., 2016) to gene expression profiles. In this way, TIMER can infer the abundance of TILCs (tumor-infiltrating immune cells), which include B cells, CD4+ T cells, CD8+ T cells, neutrophils, macrophages, and dendritic cells, in a particular sample. In our study, we assessed their correlations with the expression of CESC hub genes via different gene modules.

Estimation of immune cell type fractions
CIBERSORT (http://cibersort.stanford.edu/) (Newman et al., 2015), a data set of 547 genes, allows highly sensitive and specific discrimination of 22 human hematopoietic cell phenotypes, including B cells, T cells, natural killer cells, macrophages, dendritic cells and myeloid subsets. This approach has been previously used on gene expression profiles obtained from microarray and was used here to quantify the proportions of immune cell types that were predicted separately for each gene expression series. For
each CESC sample, the sum of all cell-type fraction estimates was set equal to 1.

**Gene set enrichment analysis**

GSEA is a computational method used to determine if a set of genes, defined *a priori*, exhibit statistically significant differences between two biological states (Subramanian *et al.*, 2005). Our study deployed this approach to first generate a systematic list of all genes relative to CCL5 expression, then elucidated the significant survival difference, which was noticed between the high and low expression groups. The recommended 1000 gene-set permutations were performed for each analysis, with CCL5 expression levels serving as phenotype labels.

**Results**

**Stromal and immune scores in CESC**

Relevant data were downloaded from TCGA on April 21, 2019 and used to assess stromal and immune scores in CESC patients. The 304 CESC cases were divided into top and bottom halves based on their immune scores, presented via the Kaplan-Meier survival curves and statue plot in Fig. 1A. We found that a longer median overall survival was displayed by the high-score cases relative to the low-score group, which was found to be statistically significant.

**Identification of DEGs in CESC**

Next, correlations between global gene expression profiles and immune scores were identified by executing the *limma* package in R. The volcano plot and heatmap in Fig. 1B, depict 425 identified DEGs, of which 295 were up-regulated and 130 were down-regulated (Fig. 1B).

**Enrichment analysis**

ClusterProfiler was deployed for functional and pathway enrichment analysis in order to explore the functions of identified DEGs. With reference to biological processes, GO analysis revealed that DEGs were significantly enriched in...
genes associated with lymphocyte-mediated immunity, as well as genes involved in complement activation, classical pathway and humoral immune response mediated by circulating immunoglobulin. Cell component analysis revealed that these DEGs are generally active on the outer surface of the external side of the plasma membrane, in the immunoglobulin complex (circulating) and in the immunoglobulin complex. Likewise, the molecular function of DEGs was significantly enriched in antigen binding, serine-type endopeptidase activity, and serine-type peptidase activity, as shown in Fig. 2A. Furthermore, KEGG pathway analysis indicated that these DEGs were significantly enriched in associations with graft-versus-host disease, cytokine-cytokine receptor interaction, natural killer cell-mediated cytotoxicity, hematopoietic cell lineage, and antigen processing and presentation, as seen in Fig. 2B.

**PPI network construction and module analysis**

The STRING database was used to construct a PPI network of DEGs in Cytoscape, which had 173 nodes and 1033 interactions (Fig. 3A). Modules with an overall high score were extracted from this network via MCODE (Fig. 3B).

![FIGURE 2. (A) GO analysis of DEGs in CESC including biological processes, cellular components and molecular function. (B) KEGG analysis of DEGs in CESC.](image-url)
Fig. 4B shows pathway enrichment analysis for the most highly significant module, indicating significantly correlated genes related to graft-versus-host disease, cytokine-cytokine receptor interaction, allograft rejection, Type-I diabetes mellitus, and natural killer cell-mediated cytotoxicity. CCL5, CCR5, CTLA4, CXCL9, CXCR3, FASLG, GZMA, GZMB, IDO1, IFNG, IL2RA, KLRD1, LAG3, PRF1, PTPRC, TBX21, and TLR8 were designated as leading module genes.

Hub gene selection
GEPIA database mining revealed significant differential expression between CESC and normal tissues, further validating the close relationship between module gene expression levels and disease onset. GEPIA-sourced data from 291 CESC patients were divided into high- and low-expression groups for overall survival (OS) analysis. We established that up-regulation of CCL5 was correlated with

FIGURE 3. (A) Protein-protein interaction network construction and (B) module analysis.
significantly better OS in CESC patients, as seen in Fig. 4A. CCL5 expression levels could, therefore, collectively serve as essential prognostic biomarkers to predict survival in CESC patients. For this reason, we further analyzed CCL5 as the designated hub gene.

**Correlation between hub genes and immune infiltration**

Tumor-infiltrating lymphocytes serve as independent predictors of sentinel lymph node status and survival in cancers (Azimi et al., 2012; Dunn et al., 2007). We therefore assessed potential CCL5 expression across infiltration levels via TIMER. This analysis revealed significant correlations with several immune cells in CESC, as presented in Figs. 4B, 4C.

**Estimation of immune cell type fractions**

As seen in Figs. 5A, 5B, CIBERSORT revealed that the fractions of CD8+ T cells and M1 macrophages were consistently higher within the high immune scores group relative to the low scores group, while the fraction of M0 macrophages was significantly lower.

**GSEA identifies a CCL5-related signaling pathway**

Gene Set Enrichment Analysis (GSEA) of low- and high-CCL5 data sets facilitated the identification of signaling pathways differentially activated in CESC. This approach revealed significant enrichment of genes involved in the activation of the immune response, cellular response to interferon-gamma, and the WNT signaling pathway, as seen in Fig. 5C.

**Discussion**

Cervical cancer is the most common tumor in the female genital tract, as well as the leading cause of morbidity and mortality among women worldwide, with approximately more than 270,000 deaths occurring yearly (Sawaya et al., 2019). Outcomes for CESC patients are suboptimal when the disease is diagnosed at an advanced stage. Survival rates for advanced-inoperable and recurrent CESC patients remain low due to locoregional and distant recurrences (Liontos et al., 2019). HPV infection status, widely known

---

**FIGURE 4.** (A) Expression levels of hub genes and their prognostic values according to the GEPIA database (B) Correlation of CCL5 expression with immune infiltration level in CESC according to TIMER database (C) Prognostic values of immune infiltration in CESC based on TIMER database.
as a cause of CIN and cervical CESC, is considered to play an essential role in patients who are locally advanced and have distant recurrences with dismal prognoses (Smith et al., 2019). Despite combined approaches such as surgery and radio-chemotherapy, it remains urgent for researchers to identify effective strategies for these currently incurable CESC patients (Cohen et al., 2019). In particular, immunotherapeutic strategies, which play a key role in the treatment of advanced-inoperable and recurrent CESC, are urgently required. Therefore, our study aims to provide insights into novel prognostic markers, ultimately offering important clues into the relationships that local immune infiltration and tumor microenvironment have with cancer etiology and tumor progression.

In the current study, we assessed immune cell function in CESC using 304 relevant samples from TCGA in order to investigate the relationship of micro-environment to CESC carcinogenesis and invasive progression. The analysis showed that 425 DEGs were detected within the assigned immune scores, including 295 up-regulated and 130 down-regulated. Functional and pathway enrichment analysis explored the identified DEGs and found them significantly enriched in the categories of lymphocyte-mediated immunity, complement activation, classical pathway, and humoral immune response mediated by circulating immunoglobulin. PPI network construction and module analysis indicated that up-regulated and down-regulated DEGs were significantly enriched in associations with graft-versus-host disease, cytokine-cytokine receptor interaction, allograft rejection, Type-I diabetes mellitus, and natural killer cell-mediated cytotoxicity. CCL5, CCR5, CTLA4, CXCL9, CXCR3, FASLG, GZMA, GZMB, IDO1, IFNG,
IL2RA, KLRD1, LG3, PRF1, PTGFR, TBX21, and TLR8 were the designated leading module genes. Using GEPIA-sourced data, we established that the up-regulated expression of CCL5 was correlated with significantly better survival in CESC patients. Therefore, CCL5 expression levels could serve as a novel prognostic biomarker for CESC patients. We further focused on CCL5 as the designated hub gene and went on to establish significant correlations with several types of immune cells in CESC samples. Then, we used CIBERSORT to estimate immune cell type fractions, which showed that CD8+ T cells, M1 macrophages, and M0 macrophages may be candidate targets for CESC therapies. According to GSEA, CCL5-related signaling pathways activated in CESC included activation of the immune response, cellular response to interferon-gamma, and pathways activated in CESC patients. Furthermore, CCL5-related signaling pathways activated in CESC included activation of the immune response, cellular response to interferon-gamma, and the WNT signaling pathway.

It has been reported that macrophage infiltration has a close relationship with poor prognosis and chemotherapy resistance in numerous types of solid cancers (Tanaka et al., 2019). A number of immunotherapeutic approaches have been employed to limit macrophage infiltration and exert potential antitumor functions (Guilbaud et al., 2019). Macrophages, implicated in suppression of antitumor immunity, can promote the initiation and malignant progression of tumor cells by extravasation, migration, invasion, and metastasis in some solid tumors. However, tumor-associated macrophages (TAMs) serve as natural targets for antitumor therapy in humans via the re-differentiation of macrophages from pro-tumoral phenotypes towards M1-type states (Cassetta and Pollard, 2018; Chen et al., 2017). In our current study, cell-type fractions of M1 macrophages were significantly higher in the high immune scores group, which indicated better overall survival. Recent research has revealed that chemokines CCL2 and CCL5 recruit macrophages which strongly transform the phenotype of macrophages in cervical carcinoma mouse models, dependent on a vaccine-induced influx of CD8 T cells (2015). Similarly, in our study, we established that up-regulated CCL5 was correlated with significantly better survival in CESC patients. Furthermore, CCL5-related signaling pathways activated in CESC included activation of the immune response, cellular response to interferon-gamma and the WNT signaling pathway.

However, our study has several limitations. Scientists explored that some immune checkpoints inhibitors, such as anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4), programmed cell death receptor (PD-1), and programmed cell death ligand 1 (PD-L1) inhibitors, are involved in lifting tumor-induced immune response suppression and revealed highly interrelated rates of PD-L1+ macrophages and regulatory T cells in the lymph nodes of metastatic CESC patients. Additional investigation will be required to further characterize the immune checkpoint function of CCL5, including both in vitro and in vivo studies for mechanistic and prospective insights (Rotman et al., 2018).

In conclusion, we provided an overview of associations between immune infiltration and overall survival in CESC patients. CCL5 was identified as a novel prognostic biomarker for CESC, as well as suggested to serve as a possible immune checkpoint and a potential target for new immunotherapies. Further functional studies could be performed to support our conclusions. In addition, several details about the specific mechanism at play here still need to be confirmed and further clarified.

Acknowledgement: The results shown here are in whole or part based upon data generated by the TCGA Research Network: http://cancergenome.nih.gov/.

Availability of Data and Materials: Our data were downloaded from TCGA.

Funding Statement: This study was funded by the National Natural Science Foundation of China (No. 81802606), Key Technology Research Project of Nantong Science and Technology Bureau (MS12017013-1), Training Program of Innovation and Entrepreneurship for College Students in Jiangsu (Nos. 201913993001Y and 2019139930211H).

Conflicts of Interest: The authors declare that there are no conflicts of interest.

References
Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G (2000). Gene ontology: Tool for the unification of biology. Nature Genetics 25: 25–29. DOI 10.1038/75556.
Azimi F, Scolyer RA, Rumcheva P, Moncrieff M, Murrali R, McCarrthy SW, Saw RP, Thompson JF (2012). Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. Journal of Clinical Oncology 30: 2678–2683. DOI 10.1200/JCO.2011.37.8539.
Bandettini WP, Kellman P, Mancini C, Booker OJ, Vasu S, Leung SW, Wilson JR, Shanhag SM, Chen MY, Ari AI (2012). MultiContrast Delayed Enhancement (MCODE) improves detection of subendocardial myocardial infarction by late gadolinium enhancement cardiovascular magnetic resonance: A clinical validation study. Journal of Cardiovascular Magnetic Resonance 14: 83. DOI 10.1186/1532-429X-14-83.
Cassetta L, Pollard JW (2018). Targeting macrophages: Therapeutic approaches in cancer. Nature Reviews Drug Discovery 17: 887–904. DOI 10.1038/nrd.2018.169.
Cohen PA, Jhingran A, Oaknin A, Denny L (2019). Cervical cancer. Lancet 393: 169–182. DOI 10.1016/S0140-6736(18)32740-X.
Chauhan SR, Bharadwaj M (2018). Gearing up T-cell immunotherapy in cervical cancer. Current Problems in Cancer 42: 175–188. DOI 10.1016/j.cjpp.2018.04.001.
Chen XJ, Han LF, Wu XG, Wei WF, Wu LF, Yi HY, Yan RM, Bai XY, Zhong M, Yu YH, Liang L, Wang W (2017). Clinical significance of CD163+ and CD68+ tumor-associated macrophages in high-risk HPV-related cervical cancer. Journal of Cancer 8: 3868–3875. DOI 10.7150/jca.21444.
De Felice F, Marchetti C, Palai A, Ostuni R, Muzii L, Tombolini V, Benedetti Panici P (2018). Immune check-point in cervical cancer. Critical Reviews in Oncology/Hematology 129: 40–43. DOI 10.1016/j.critrevonc.2018.06.006.
Dunn GP, Dunn IF, Curry WT (2007). Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human glioma. Cancer Immunology 7: 12.

Dyer BA, Zamarin D, Eskandar RN, Mayadev JM (2019). Role of immunotherapy in the management of locally advanced and recurrent/metastatic cervical cancer. Journal of the National Comprehensive Cancer Network 17: 91–97. DOI 10.6004/jnccn.2018.7108.

Guilbaud E, Gautier EL, Yvan-Charvet I (2019). Macrophage origin, metabolic reprogramming and il-1 signaling: promises and pitfalls in lung cancer. Cancers 11: 298. DOI 10.3390/cancers11030298.

He A, Ji R, Shao J, He C, Jin M, Xu Y (2016). TLR4-MyD88-TRAF6-Dyer BA, Zamarin D, Eskandar RN, Mayadev JM (2019). Role of immunotherapy in the management of locally advanced and recurrent/metastatic cervical cancer. Journal of the National Comprehensive Cancer Network 17: 91–97. DOI 10.6004/jnccn.2018.7108.

Li B, Severson E, Pignon JC, Zhao H, Li T, Novak J, Jiang P, Shen H, Aster JC, Rodig S, Signoretti S, Liu JS, Liu XS (2016). Comprehensive analyses of tumor immunity: Implications for cancer immunotherapy. Genome Biology 17: 805. DOI 10.1186/s13059-016-1028-7.

Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, Li B, Liu XS (2017). TIMER: A web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Research 77: e108–e110. DOI 10.1158/0008-5472.CAN-17-0307.

Liontos M, Kyriazoglou A, Dimitriadis I, Dimopoulos MA, Bamias A (2019). Systemic therapy in cervical cancer: 30 years in review. Critical Reviews in Oncology/Hematology 137: 9–17. DOI 10.1016/j.critrevonc.2019.02.009.

Mangino G, Chiantore MV, Iuliano M, Fiorucci G, Romeo G (2016). Inflammatory microenvironment and human papillomavirus-induced carcinogenesis. Cytokine & Growth Factor Reviews 30: 103–111. DOI 10.1016/j.cytogfr.2016.03.007.

Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD, Diehn M, Alizadeh AA (2015). Robust enumeration of cell subsets from tissue expression profiles. Nature Methods 12: 453–457. DOI 10.1038/nmeth.3337.

Ogata H, Goto S, Sato K, Fujibuchi W, Bono H, Kanehisa M (1999). KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Research 27: 29–34. DOI 10.1093/nar/27.1.29.

Ramanathan P, Dhandapani H, Jayakumar H, Seetharaman A, Thangarajan R (2018). Immunotherapy for cervical cancer: Can it do another lung cancer? Current Problems in Cancer 42: 148–160. DOI 10.1016/j.cprccancer.2017.12.004.

Ritchie ME, Shipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK (2015). Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Research 43: e47–e47. DOI 10.1093/nar/gkv007.

Rotman J, Mom CH, Jordanova ES, De Gruijl TD, Kenter GG (2018). ‘DURVIT’: A phase-1 trial of single low-dose durvalumab (Medi4736) Intratumourally injected in cervical cancer: safety, toxicity and effect on the primary tumour- and lymph node microenvironment. BMC Cancer 18: 4. DOI 10.1186/s12885-018-4764-0.

Sawaya GF, Smith-Mccune K, Kuppermann M (2019). Cervical cancer screening: More choices in 2019. JAMA 321: 284–287. DOI 10.1001/jama.2019.4595.

Sichero L, Rollison DE, Amorrottu RP, Tommasino M (2019). Beta human papillomavirus and associated diseases. Acta Cytologica 63: 100–108. DOI 10.1159/000492659.

Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D, Wender RC (2019). Cancer screening in the United States, 2019: A review of current American Cancer Society guidelines and current issues in cancer screening. CA: A Cancer Journal for Clinicians 69: 184–210. DOI 10.3322/caac.21557.

Smoot ME, Ono K, Ruscheinski J, Wang PL, Ideker T (2011). Cytoscape 2.8: New features for data integration and network visualization. Bioinformatics 27: 431–432. DOI 10.1093/bioinformatics/btq675.

Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP (2005). Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences of the United States of America 102: 15545–15550. DOI 10.1073/pnas.0506580102.

Szklarczyk D, Franceschini A, Wyder S, Forsslund K, Keller D, Huerta-Cepas J, Simonovic M, Roth A, Santos A, Tsafou KP, Kuhn M, Bork P, Jensen LJ, Von Mering C (2015). STRING v10: Protein–protein interaction networks, integrated over the tree of life. Nucleic Acids Research 43: D447–D452. DOI 10.1093/nar/gku1003.

Tanaka T, Terai Y, Ohmichi M (2019). Association of matrix metalloproteinase-9 and decorin expression with the infiltration of cervical cancer. Oncology Letters 17: 1306–1312.

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z (2017). GEPIA: A web resource for comparing biological themes among gene clusters. Nucleic Acids Research 45: W174–W180. DOI 10.1093/nar/gkw493.